Sally C. Pipes

Commentary

Republicans are right to reform Medicaid

House Republicans held the mark-up last week for their reconciliation package, which includes several significant reforms to Medicaid, the federal-state entitlement that provides health benefits to roughly one in five Americans. The package is not perfect. But it would restore some measure of fiscal sanity to the program by, among ...
Commentary

President Trump Hasn’t Given Up on Hospital Price Transparency

For markets to function efficiently, consumers need to know how much things cost. This is as true for eggs and milk as it is for medical care. And it was this very insight that motivated the rule that President Donald J. Trump implemented during his first term in 2019 ordering ...
Commentary

Direct-To-Consumer Ozempic Sales Are A Win For Patients And Drug Makers

Google Wegovy. Or Zepbound. The search results offer a preview of a direct-to-consumer future for prescription drugs. The brand-name drugs’ homepages generally get top billing. But not far down are ads for telehealth companies promising access to the drugs or others with the same active pharmaceutical ingredient, or API, without ...
Commentary

Is Era of Biomedical Innovation Wins Against Cancer Over?

For evidence of the astounding progress made by medical science in recent decades, look no further than the Annual Report to the Nation on the Status of Cancer, which was jointly issued by the American Cancer Society, the Centers for Disease Control and Prevention, the North American Association of Central ...
Commentary

A Most Flawed Notion: Medicaid ‘Fix’ Will Worsen 340B Crisis

Congressional Republicans are under pressure to find savings to make the math in their budget reconciliation package add up. Medicaid, which accounts for just under 10% of federal spending, has become an obvious target. But instead of addressing the flawed incentives driving the program’s unsustainability, the Trump administration is pushing ...
Commentary

Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments

Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Drug Importation

Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”

Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Commentary

Why Are Republicans Acquiescing To Tax Hikes?

The White House is advancing a policy that would raise drug prices, stifle medical innovation, and hand China a strategic edge in the race for global technological dominance. No, Joe Biden hasn’t somehow returned to office. This time, the ill-advised idea — tariffs on imported medicines — comes from Donald ...
Commentary

Medicaid isn’t a federal entitlement

Sen. Bill Cassidy (R-LA) recently ripped into progressives for opposing Medicaid reform. “Medicaid is meant to be a state-federal partnership,” Cassidy, who has an M.D., wrote on X. “States are supposed to pay for 40% of the cost. Most states are paying for less than 15%. … People should not ...
Commentary

Medicaid Is Not A Test Lab For Foreign Price Controls

In a desperate bid to claim fiscal discipline without touching entitlements, President Donald J. Trump is pushing congressional Republicans to adopt a “most favored nation” (MFN) drug pricing model for Medicaid. This policy would tie Medicaid reimbursements to the lowest prices paid in other developed countries—countries where government officials dictate ...
Commentary

Republicans are right to reform Medicaid

House Republicans held the mark-up last week for their reconciliation package, which includes several significant reforms to Medicaid, the federal-state entitlement that provides health benefits to roughly one in five Americans. The package is not perfect. But it would restore some measure of fiscal sanity to the program by, among ...
Commentary

President Trump Hasn’t Given Up on Hospital Price Transparency

For markets to function efficiently, consumers need to know how much things cost. This is as true for eggs and milk as it is for medical care. And it was this very insight that motivated the rule that President Donald J. Trump implemented during his first term in 2019 ordering ...
Commentary

Direct-To-Consumer Ozempic Sales Are A Win For Patients And Drug Makers

Google Wegovy. Or Zepbound. The search results offer a preview of a direct-to-consumer future for prescription drugs. The brand-name drugs’ homepages generally get top billing. But not far down are ads for telehealth companies promising access to the drugs or others with the same active pharmaceutical ingredient, or API, without ...
Commentary

Is Era of Biomedical Innovation Wins Against Cancer Over?

For evidence of the astounding progress made by medical science in recent decades, look no further than the Annual Report to the Nation on the Status of Cancer, which was jointly issued by the American Cancer Society, the Centers for Disease Control and Prevention, the North American Association of Central ...
Commentary

A Most Flawed Notion: Medicaid ‘Fix’ Will Worsen 340B Crisis

Congressional Republicans are under pressure to find savings to make the math in their budget reconciliation package add up. Medicaid, which accounts for just under 10% of federal spending, has become an obvious target. But instead of addressing the flawed incentives driving the program’s unsustainability, the Trump administration is pushing ...
Commentary

Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments

Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Drug Importation

Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”

Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Commentary

Why Are Republicans Acquiescing To Tax Hikes?

The White House is advancing a policy that would raise drug prices, stifle medical innovation, and hand China a strategic edge in the race for global technological dominance. No, Joe Biden hasn’t somehow returned to office. This time, the ill-advised idea — tariffs on imported medicines — comes from Donald ...
Commentary

Medicaid isn’t a federal entitlement

Sen. Bill Cassidy (R-LA) recently ripped into progressives for opposing Medicaid reform. “Medicaid is meant to be a state-federal partnership,” Cassidy, who has an M.D., wrote on X. “States are supposed to pay for 40% of the cost. Most states are paying for less than 15%. … People should not ...
Commentary

Medicaid Is Not A Test Lab For Foreign Price Controls

In a desperate bid to claim fiscal discipline without touching entitlements, President Donald J. Trump is pushing congressional Republicans to adopt a “most favored nation” (MFN) drug pricing model for Medicaid. This policy would tie Medicaid reimbursements to the lowest prices paid in other developed countries—countries where government officials dictate ...
Scroll to Top